close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Arcturus Therapeutics Holdings Inc.

< Previous 1 2 3 Next >
Arcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Appoints John Markels, Ph.D. to its Board of Directors
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Present at the Following Investor Conferences in November
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Attend the Following Investor Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Attend the Following Investor Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Participate in the Barclays Global Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today